Regeneron Pharmaceuticals Restricted Cash increased by 19.4% to $8.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 185.7%, from $2.80M to $8.00M.
An increase may signal higher debt service requirements or increased collateral obligations, while a decrease may indicate the release of restricted funds.
Cash balances that are legally or contractually set aside for specific purposes, such as debt service reserves, collater...
Common in capital-intensive industries like energy where project financing requires specific reserve accounts.
restricted_cash| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.50M | $12.50M | $13.50M | $13.50M | $13.50M | $12.50M | $5.50M | $7.90M | $0.00 | $7.50M | $0.00 | $2.80M | $19.80M | $6.70M | $8.00M |
| QoQ Change | — | +0.0% | +8.0% | +0.0% | +0.0% | -7.4% | -56.0% | +43.6% | -100.0% | — | -100.0% | — | +607.1% | -66.2% | +19.4% |
| YoY Change | — | — | — | +8.0% | +8.0% | -7.4% | -59.3% | -41.5% | -100.0% | +36.4% | -100.0% | — | +164.0% | — | +185.7% |